EUVIMEDEUVIMED entdecken
Crossref

Isoliensinine suppresses chondrocytes pyroptosis against osteoarthritis via the MAPK/NF-κB signaling pathway

Zhengze Zhang, Jizhi Ma, Yanzi Yi, Shuai Wang, Yuewen He, Yurui Liu, Kai Meng, Yong Wang, Wuhua Ma

International Immunopharmacology · 2024-12 · 143 · 113589

DOI: 10.1016/j.intimp.2024.113589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Zhengze Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China; Lingnan Medical Research Center, Guangzhou U…. Hauptthemen laut MEDLINE: Pyroptosis, Chondrocytes, NF-kappa B, Osteoarthritis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Isoliensinine is an active compound derived from Nelumbo nucifera which has long been used for its anti-inflammatory properties. However, the mechanism of Isoliensinine in the treatment of osteoarthritis is poorly known. PURPOSE: The present study aims to investigate whether Isoliensinine could alleviate osteoarthritis by regulating MAPK/NF-κB signaling pathway-mediated pyroptosis. METHODS: Network pharmacology and KEGG enrichment analysis were used to identify the therapeutic targets of Isoliensinine for OA. Molecular docking was used to confirm the binding ability of Isoliensinine and related proteins. In vitro, chondrocytes were stimulated with IL-1β to construct an inflammatory model and treated with Isoliensinine. The viability of the cells was assessed using the CCK-8 kit. The apoptosis rate of cells was measured using Annexin V-FITC/PI assay. And assessed the levels of ROS, lipid-ROS, and mitochondrial membrane potential. Corresponding assay kits were utilized to measure the levels of MDA and SOD. Subsequently, the anabolic and catabolic markers in chondrocytes, alongside inflammatory targets were measured by RT-PCR and Western blot. The expression level of pyroptosis and MAPK/NF-κB signaling pathway-related targets was examined. Furthermore, we constructed a rat osteoarthritis model using ACLT surgery. We then assessed the progression of osteoarthritis by Micro-CT, H&E staining, S&F staining and immunohistochemistry. RESULTS: Enrichment analysis showed that Isoliensinine treatment of osteoarthritis may be through the MAPK/NF-κB pathway, and molecular docking showed that Isoliensinine and MAPK/NF-κB pathway proteins had a good binding ability. Data showed that Isoliensinine could reduce ECM degradation and inflammation, and inhibit IL-1β-induced apoptosis. It also mitigated ROS and LPO activation, regulated mitochondrial dysfunction, and reduced intracellular oxidative stress levels. Furthermore, Western blot showed that Isoliensinine also inhibited the activation of the MAPK/NF-κB pathway, thereby inhibiting the pyroptosis of chondrocytes. In vivo, Micro-CT, H&E staining and S&F staining results showed that Isoliensinine could effectively improve joint damage caused by osteoarthritis. And IHC analyses indicated NLRP3, MMP3 protein expression were significantly diminished and Collagen II expression was increased in the Isoliensinine treatment groups. CONCLUSION: In conclusion, our study suggested that Isoliensinine mitigates ECM degradation, oxidative stress, chondrocytes apoptosis, and pyroptosis through the inhibition of the MAPK and NF-κB pathways, thereby delaying the progression of osteoarthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyroptosisChondrocytesNF-kappa BOsteoarthritisMolecular Docking SimulationRats, Sprague-DawleyAnimalsRatsSignal TransductionAnti-Inflammatory AgentsCells, CulturedMaleHumansInterleukin-1betaMAP Kinase Signaling System

Stichwörter der Autor:innen

IsoliensinineMAPK/NF-κB signaling pathwayOsteoarthritisPyroptosis

Substanzen

NF-kappa BAnti-Inflammatory AgentsInterleukin-1beta

Autor:innen und Institutionen

  • The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China.
  • The Third Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China.
  • The Fifth Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China.
  • Department of Orthopaedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, PR China. Electronic address: sdmengkai2016@163.com.
  • Department of Anesthesiology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China; State Key Laboratory of Traditional Chinese Medicine Syndrome, The First Affiliated Ho…
  • Department of Anesthesiology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China. Electronic address: tuesdaymorninggz@126.com.

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Bureau

Zitieren

APA

Zhang, Z., Ma, J., Yi, Y., Wang, S., He, Y., Liu, Y., Meng, K., Wang, Y., & Ma, W. (2024). Isoliensinine suppresses chondrocytes pyroptosis against osteoarthritis via the MAPK/NF-κB signaling pathway. International Immunopharmacology, 143, 113589. https://doi.org/10.1016/j.intimp.2024.113589

Vancouver

Zhang Z, Ma J, Yi Y, Wang S, He Y, Liu Y, et al. Isoliensinine suppresses chondrocytes pyroptosis against osteoarthritis via the MAPK/NF-κB signaling pathway. International Immunopharmacology. 2024;143:113589. doi:10.1016/j.intimp.2024.113589

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhengze and Ma, Jizhi and Yi, Yanzi and Wang, Shuai and He, Yuewen and Liu, Yurui and Meng, Kai and Wang, Yong and Ma, Wuhua},
  title = {Isoliensinine suppresses chondrocytes pyroptosis against osteoarthritis via the MAPK/NF-κB signaling pathway},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {143},
  pages = {113589},
  doi = {10.1016/j.intimp.2024.113589}
}
Kostenlos starten →